The data shows that downregulating PU.1 promotes the expression of immunoregulatory proteins on microglia that help protect cognitive function.

Triple therapy approach that hits cancer from multiple angles at once could be a game-changer against breast cancers that no longer respond to hormone treatment.

FDA approved KYGEVVI, the first and only treatment of thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients.

The goal of the project is to develop novel approaches that strengthen and reduce the costs of domestic mAb biomanufacturing to protect against and treat infection by filoviruses.